Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

2.

Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11.

Raut R, Rouleau JL, Blais C Jr, Gosselin H, Molinaro G, Sirois MG, Lepage Y, Crine P, Adam A.

Am J Physiol. 1999 May;276(5 Pt 2):H1769-79.

3.

Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors GW660511X and omapatrilat.

Heudi O, Ramirez-Molina C, Marshall P, Amour A, Peace S, McKeown S, Abou-Shakra F.

J Pept Sci. 2002 Nov;8(11):591-600.

PMID:
12487427
4.
5.
6.

Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.

Campbell DJ, Anastasopoulos F, Duncan AM, James GM, Kladis A, Briscoe TA.

J Pharmacol Exp Ther. 1998 Nov;287(2):567-77.

7.

Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.

Blais C Jr, Fortin D, Rouleau JL, Molinaro G, Adam A.

J Pharmacol Exp Ther. 2000 Nov;295(2):621-6.

8.

The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.

Sulpizio AC, Pullen MA, Edwards RM, Brooks DP.

J Pharmacol Exp Ther. 2004 Jun;309(3):1141-7. Epub 2004 Feb 9.

9.

Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat.

Kubota E, Dean RG, Hubner RA, Casley DJ, Johnston CI, Burrell LM.

Clin Sci (Lond). 2003 Sep;105(3):339-45.

PMID:
12741953
10.
11.

Metabolism of bradykinin by peptidases in the lung.

Dragović T, Igić R, Erdös EG, Rabito SF.

Am Rev Respir Dis. 1993 Jun;147(6 Pt 1):1491-6.

PMID:
8389109
12.
13.

Kininase II-type enzymes. Their putative role in muscle energy metabolism.

Dragović T, Minshall R, Jackman HL, Wang LX, Erdös EG.

Diabetes. 1996 Jan;45 Suppl 1:S34-7.

PMID:
8529798
14.

Pathways for angiotensin-(1---7) metabolism in pulmonary and renal tissues.

Allred AJ, Diz DI, Ferrario CM, Chappell MC.

Am J Physiol Renal Physiol. 2000 Nov;279(5):F841-50.

15.

Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406.

Sulpizio AC, Pullen MA, Edwards RM, Louttit JB, West R, Brooks DP.

J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13. Epub 2005 Sep 6.

16.

Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study.

Blais C Jr, Drapeau G, Raymond P, Lamontagne D, Gervais N, Venneman I, Adam A.

Am J Physiol. 1997 Nov;273(5 Pt 2):H2263-71.

17.

Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema.

Fryer RM, Segreti J, Banfor PN, Widomski DL, Backes BJ, Lin CW, Ballaron SJ, Cox BF, Trevillyan JM, Reinhart GA, von Geldern TW.

Br J Pharmacol. 2008 Mar;153(5):947-55. Epub 2007 Dec 17.

18.

Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase.

French JF, Flynn GA, Giroux EL, Mehdi S, Anderson B, Beach DC, Koehl JR, Dage RC.

J Pharmacol Exp Ther. 1994 Jan;268(1):180-6.

PMID:
8301555
19.

Altered cardiac bradykinin metabolism in experimental diabetes caused by the variations of angiotensin-converting enzyme and other peptidases.

Adam A, Leclair P, Montpas N, Koumbadinga GA, Bachelard H, Marceau F.

Neuropeptides. 2010 Apr;44(2):69-75. doi: 10.1016/j.npep.2009.09.004.

PMID:
19836835
20.

Degradation of bradykinin, a cardioprotective substance, during a single passage through isolated rat-heart.

Ahmad M, Zeitlin IJ, Parratt JR, Pitt AR.

Arch Pharm Res. 2006 Mar;29(3):241-8.

PMID:
16596998

Supplemental Content

Support Center